Adagio Medical Updates Investor Deck: FDA Approval Expected Q4 2026, Cash at $7.7M
ADGM sits 90% above its 52-week low of $0.363 on light trading volume (0.1× avg).
Summary
Adagio Medical filed an updated investor presentation detailing its regulatory timeline, market opportunity, and financial position, including $7.7M in cash and FDA approval expected by Q4 2026.
Key Events · Product Development and Regulatory · ADGM
-
Updated Investor Presentation Filed
Adagio Medical made available an updated corporate presentation dated August 13, 2026, for use in investor meetings.
-
FDA Approval Timeline Reaffirmed
The presentation reiterates expected FDA approval of vCLAS in Q4 2026/Q1 2027, with limited market release in 1H 2027.
-
Financial Position Disclosed
Cash and cash equivalents of $7.7M as of June 30, 2026, against $24.8M in convertible notes payable, highlighting a tight liquidity position.
-
Market Opportunity Highlighted
The presentation cites a $5.8B global VT ablation market with only 6% penetration, positioning vCLAS as a purpose-built solution.
Analysis · ADGM · Industrial Applications And Services
The updated corporate presentation provides a consolidated view of Adagio's near-term catalysts and financial position. It reiterates the FDA approval timeline for vCLAS (Q4 2026/Q1 2027) and discloses a cash balance of $7.7M against $24.8M in convertible notes, underscoring the liquidity crunch previously flagged in the Q2 10-Q. The presentation also highlights the $5.8B VT ablation market opportunity and the company's breakthrough device designation, which are central to the investment thesis.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADGM was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.36 to $2.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.